Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alpine Immune Sciences Inc

ALPN
Current price
64.55 USD +0.12 USD (+0.19%)
Last closed 64.43 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 224 062 976 USD
Yield for 12 month +794.04 %
1Y
3Y
5Y
10Y
15Y
ALPN
21.11.2021 - 28.11.2021

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. Address: 188 East Blaine Street, Seattle, WA, United States, 98102

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

62 USD

P/E ratio

Dividend Yield

Current Year

+58 876 000 USD

Last Year

+30 064 000 USD

Current Quarter

+30 853 000 USD

Last Quarter

+10 043 000 USD

Current Year

+58 300 000 USD

Last Year

+29 467 000 USD

Current Quarter

+30 705 000 USD

Last Quarter

+9 897 000 USD

Key Figures ALPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -43 674 000 USD
Operating Margin TTM 5.01 %
PE Ratio
Return On Assets TTM -8.3 %
PEG Ratio
Return On Equity TTM -12.69 %
Wall Street Target Price 62 USD
Revenue TTM 58 876 000 USD
Book Value 5.43 USD
Revenue Per Share TTM 1.18 USD
Dividend Share
Quarterly Revenue Growth YOY 1011.4 %
Dividend Yield
Gross Profit TTM -40 179 000 USD
Earnings Share -0.64 USD
Diluted Eps TTM -0.64 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -54.66 %

Dividend Analytics ALPN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:4
Payout Ratio
Last Split Date 25.07.2017
Dividend Date 25.07.2017

Stock Valuation ALPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 66.2856
Price Sales TTM 71.6783
Enterprise Value EBITDA -124.2599
Price Book MRQ 12.8686

Financials ALPN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALPN

For 52 weeks

6.71 USD 64.57 USD
50 Day MA 38.32 USD
Shares Short Prior Month 5 610 741
200 Day MA 20.42 USD
Short Ratio 4.15
Shares Short 5 284 601
Short Percent 13.14 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics